BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
This marks the first ex-China regulatory filing for tislelizumab, following approval in five indications in China The accepted BLA, filed...










